GR3033761T3 - In vitro generation of human dendritic cells and uses thereof. - Google Patents

In vitro generation of human dendritic cells and uses thereof.

Info

Publication number
GR3033761T3
GR3033761T3 GR20000401457T GR20000401457T GR3033761T3 GR 3033761 T3 GR3033761 T3 GR 3033761T3 GR 20000401457 T GR20000401457 T GR 20000401457T GR 20000401457 T GR20000401457 T GR 20000401457T GR 3033761 T3 GR3033761 T3 GR 3033761T3
Authority
GR
Greece
Prior art keywords
dendritic cells
human dendritic
adoptive immunotherapy
vitro generation
vitro
Prior art date
Application number
GR20000401457T
Other languages
English (en)
Inventor
Jacques Banchereau
Christophe Caux
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of GR3033761T3 publication Critical patent/GR3033761T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
GR20000401457T 1992-03-30 2000-06-23 In vitro generation of human dendritic cells and uses thereof. GR3033761T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP92400879A EP0563485A1 (en) 1992-03-30 1992-03-30 In vitro generation of human dendritic cells and uses thereof
EP93908477A EP0633930B1 (en) 1992-03-30 1993-03-29 In vitro generation of human dendritic cells
PCT/US1993/002639 WO1993020186A1 (en) 1992-03-30 1993-03-29 In vitro generation of human dendritic cells and uses thereof

Publications (1)

Publication Number Publication Date
GR3033761T3 true GR3033761T3 (en) 2000-10-31

Family

ID=8211642

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000401457T GR3033761T3 (en) 1992-03-30 2000-06-23 In vitro generation of human dendritic cells and uses thereof.

Country Status (14)

Country Link
EP (2) EP0563485A1 (el)
JP (1) JP3492361B2 (el)
KR (1) KR100223395B1 (el)
AT (1) ATE192189T1 (el)
AU (2) AU682466B2 (el)
CA (1) CA2133316C (el)
DE (1) DE69328481T2 (el)
DK (1) DK0633930T3 (el)
ES (1) ES2145047T3 (el)
GR (1) GR3033761T3 (el)
MX (1) MX9301753A (el)
NZ (1) NZ251585A (el)
PT (1) PT633930E (el)
WO (1) WO1993020186A1 (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0633929T3 (da) * 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
DE4337396A1 (de) * 1993-10-26 1995-04-27 Beiersdorf Ag Humane Zellinien mit Langerhans-Zell-Charakteristik
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5648248A (en) * 1994-12-30 1997-07-15 Boehringer Ingelheim International Gmbh Methods for producing differentiated cells from immature hematopoietic cells
US5643786A (en) * 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US6340981B1 (en) 1997-06-30 2002-01-22 Sun Microsystems, Inc. Method and apparatus for stroke substitution
US5871728A (en) 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation
US6121044A (en) * 1995-07-12 2000-09-19 Dendreon Corporation Potent antigen presenting cell composition
US7361330B2 (en) 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてｔ細胞を活性化するための方法及び組成物
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
US7659119B2 (en) 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US5811297A (en) * 1996-03-07 1998-09-22 Amba Biosciences, Llc Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages
US6008004A (en) 1996-10-04 1999-12-28 Becton Dickinson & Company Identification of a CD34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues
WO1998020140A1 (en) 1996-11-06 1998-05-14 The Regents Of The University Of California Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
AU9374198A (en) * 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
EP0922758B1 (en) 1997-10-27 2009-04-15 Rockefeller University Methods and compositions for obtaining mature dendritic cells
CA2321093A1 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
JP2001061469A (ja) * 1999-08-24 2001-03-13 Japan Science & Technology Corp 免疫応答誘導樹状細胞の調製方法
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7419957B2 (en) 2001-08-22 2008-09-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
TW200502391A (en) 2003-05-08 2005-01-16 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
WO2007055902A1 (en) 2005-11-03 2007-05-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides and methods of use for treating and preventing cancer
CA2705486C (en) 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
US8604166B2 (en) 2008-09-02 2013-12-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Melanoma antigen peptide and uses thereof
US9266922B2 (en) 2011-06-01 2016-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antigen peptide and uses thereof
WO2013175256A1 (en) 2012-05-22 2013-11-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Novel melanoma antigen peptide and uses thereof
AU2012380681A1 (en) 2012-05-22 2014-10-30 Centre National De La Recherche Scientifique (Cnrs) Novel melanoma antigen peptide and uses thereof
JP2017515795A (ja) 2014-04-01 2017-06-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 単離されたドナーｍｈｃ由来ペプチド及びその使用
EP3126374B1 (en) 2014-04-01 2018-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) An isolated donor mhc-derived peptide and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002531A1 (en) * 1989-08-17 1991-03-07 Peter Maccallum Cancer Institute Method for the modulation of haemopoiesis in a mammal
US5128259A (en) * 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
US5622853A (en) * 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor

Also Published As

Publication number Publication date
KR100223395B1 (ko) 1999-10-15
JP3492361B2 (ja) 2004-02-03
JPH07505527A (ja) 1995-06-22
EP0633930A1 (en) 1995-01-18
DE69328481T2 (de) 2000-09-07
AU3928993A (en) 1993-11-08
KR950700989A (ko) 1995-02-20
AU3155897A (en) 1997-11-20
WO1993020186A1 (en) 1993-10-14
AU682466B2 (en) 1997-10-09
PT633930E (pt) 2000-09-29
CA2133316C (en) 2005-05-24
DK0633930T3 (da) 2000-09-18
ATE192189T1 (de) 2000-05-15
EP0563485A1 (en) 1993-10-06
CA2133316A1 (en) 1993-10-14
DE69328481D1 (de) 2000-05-31
EP0633930B1 (en) 2000-04-26
NZ251585A (en) 1997-07-27
MX9301753A (es) 1993-09-01
ES2145047T3 (es) 2000-07-01

Similar Documents

Publication Publication Date Title
GR3033761T3 (en) In vitro generation of human dendritic cells and uses thereof.
AU645747B2 (en) A novel antibody delivery system for biological response modifiers
PT633929E (pt) Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
HU9201712D0 (en) A mammalian cytokine, il-11
IL97023A0 (en) Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
EP0337256A3 (de) Verfahren zur Herstellung pharmazeutischer Mischungen
CA2148712A1 (en) Peripheralization of hematopoietic stem cells
DE69332688D1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
NZ281482A (en) The stimulation of erythropoiesis using thrombopoietin and erythropoietin
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
Bungard et al. The combination of interleukin-2 and interferon effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29
ES8600518A1 (es) Metodo in vitro para detectar un estado maligno en un paciente humano.
D'Arena et al. Circulating hematopoietic progenitor cells in leukapheresis: flow cytometric estimation
Fischer et al. Bone marrow macrophages induced to antigen presentation by lymphokines interact selectively with distinct T cells
ES2080114T3 (es) Procedimiento para preparar un factor inhibidor de la metastasis.
TW221711B (en) N-AFP monoclonal antibody and method of preparation thereof
Herberman Summary of Workshop on “Lymphokines Activating Cells for Killer Functions”
MX9708989A (es) Terapia de celulas alogeneicas para el cancer despues del transplante de celulas madre alogeneicas.